Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of brown alga polysaccharide sulfate in preventing and treating Parkinson's disease

A technology of fucoidan and Parkinson's disease, applied in the field of biomedicine, can solve problems such as movement disorders, unsatisfactory long-term curative effect, and fluctuating symptoms, and achieve the effect of less toxic and side effects, good use effect and high safety

Active Publication Date: 2011-11-02
CAPITAL UNIVERSITY OF MEDICAL SCIENCES +1
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, L-DOPA itself cannot delay the further necrosis of DA neurons, and the long-term curative effect is unsatisfactory, and there may be severe side effects such as symptom fluctuations and movement disorders. Therefore, people have been trying to find a drug that can delay the development of DA neurons. Degenerative necrosis, a drug that has a nutritional protective effect on DA neurons

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of brown alga polysaccharide sulfate in preventing and treating Parkinson's disease
  • Use of brown alga polysaccharide sulfate in preventing and treating Parkinson's disease
  • Use of brown alga polysaccharide sulfate in preventing and treating Parkinson's disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0058] The preparation of embodiment 1 laminaria fucoidan sulfate ester

[0059] After the kelp is crushed, distilled water is added for boiling water extraction, the extract is filtered with diatomaceous earth, the filtrate is dialyzed with running water for one day, and then dialyzed with distilled water for one day, the dialysate is concentrated, and ethanol is added to a concentration of 75% to precipitate, and the precipitate is dried to obtain Crude Fucoidan Sulfate. Redissolve the crude product in water at 0.05mol / L MgCl 2 In the presence of 20% ethanol precipitation to remove water-soluble alginate, the filtrate is dialyzed and concentrated, then 75% ethanol precipitates, and after drying, the purified fucoidan sulfate is obtained. After analysis, kelp fucoidan sulfate is mainly a sulfated polysaccharide composed of fucose and galactose. Among them, the content of fucose is 31%, and the content of sulfate group is 32%. The average molecular weight is 180KD.

Embodiment 2

[0060] Embodiment 2 Preparation of low molecular weight laminaria fucoidan sulfate F1

[0061] Take kelp fucoidan sulfate 50g and make a 1.5% aqueous solution, add 30mM ascorbic acid and 30mM hydrogen peroxide to the solution, and react at room temperature for 2 hours. The reaction solution was dialyzed against tap water and distilled water using a dialysis bag with a molecular weight cutoff of 3600 Da, concentrated, and freeze-dried. A low molecular weight fucoidan sulfate sample F1 was obtained. The results of chemical analysis of F1 showed that the content of fucose was 30%, the content of sulfate groups was 31%, and the average molecular weight was 7KD.

Embodiment 3

[0062] The preparation of embodiment 3 fucoidan sulfate injection

[0063] Take 100 g of fucoidan sulfate prepared in Example 1, add 1000 ml of water for injection and 100 g of mannitol, adjust the pH value to 7.0, subpackage, and freeze-dry.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a novel application of fucoidan sulfate in prevention and cure of a parkinson disease. According to the experiments of an isolated PD cell model and an in vivo animal model, fucoidan sulfate has a certain neuroprotection effect on DA cholinergic neurons of the PD cell model and animal model and can prevent and cure the PD disease. The fucoidan sulfate of the invention can be natural polysaccharide extracts obtained form brown alga such as kelp, focus, bladder wrack, sea-tangle or chorda filum and also can be materials such as low molecular weight SSPSA or oligosaccharide which are obtained through the degradation of fucoidan sulfate.

Description

technical field [0001] The invention relates to a new application of fucoidan sulfate in treating nervous system diseases, in particular to the application of fucoidan sulfate in preventing and treating Parkinson's disease, and belongs to the field of biomedicine. Background technique [0002] Fucoidan sulfate is a kind of sulfated polysaccharide containing fucose, which exists in brown algae and was first extracted from kelp palmate by Kylin in 1913 with dilute acid. Kylin separated the L-fucose after hydrolyzing the extract. He named this polysaccharide fucoidin. Now it is generally named fucoidan according to the naming principle of polysaccharides. The Chinese name is fucoidan, fucoidan, and fucoidan. , fucoidan sulfate, fucoidan or fucoidan sulfate. Now people have a relatively clear understanding of the composition of fucoidan sulfate esters. It is a type of polysaccharide with very complex chemical composition and structure. It is mainly composed of fucose and sulfat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/737A61K36/03A61P25/28
Inventor 王晓民罗鼎真张全斌
Owner CAPITAL UNIVERSITY OF MEDICAL SCIENCES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com